{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00025409", "CSN": null, "TRF": "ORD_1523346_01", "MRN": "13896872", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1238892", "clinicalId": "1240262", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1523346_01", "SampleName": "US1458779.01", "Version": "0", "Sample": {"FM_Id": "ORD_1523346_01", "SampleId": "US1458779.01", "BlockId": "nan", "TRFNumber": "ORD_1523346_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_12_14", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "64", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10037", "MRN": "13896872", "FullName": "\u5f35\u83ef\u6b66", "FirstName": "Hua_Wu", "LastName": "Chang", "SubmittedDiagnosis": "Prostate acinar adenocarcinoma", "Gender": "Male", "DOB": "1958_09_26", "OrderingMD": "\u5f35\u5ef6\u9a4a", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_12_07", "ReceivedDate": "2022-12-23 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Prostate Cancer"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "14", "clinicalTrialCount": "2", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "CBFB", "isVUS": "true", "variantName": "E163G"}, {"geneName": "CD274 (PD_L1)", "isVUS": "true", "variantName": "L142S"}, {"geneName": "CUL3", "isVUS": "true", "variantName": "V723G"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "R270H"}, {"geneName": "KIT", "isVUS": "true", "variantName": "S713F"}, {"geneName": "PALB2", "isVUS": "true", "variantName": "V221I"}, {"geneName": "SYK", "isVUS": "true", "variantName": "amplification"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "AR", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "AR encodes the androgen receptor, a nuclear receptor that binds to testosterone and dihydroxytestosterone. AR is frequently amplified and overexpressed in castration_resistant prostate cancer (CRPC), also called hormone_refractory prostate cancer (Niraula et al., 2012; 22124843). Aberrant activation of AR through mutation and amplification of AR has been shown to be fundamental to prostate cancer progression; AR amplification is rare in hormone_naive prostate cancer (Merson et al., 2014; 24481405, Visakorpi et al., 1995; 7795646, Koivisto et al., 1997; 9000575, Bubendorf et al., 1999; 10029066, Linja et al., 2001; 11325816), but has been reported for 13_49% of patients with castration_resistant prostate cancer (CRPC) following progression on androgen_deprivation therapy or AR pathway inhibitors, such as abiraterone or enzalutamide (Palmberg et al., 2000; 11061898, Visakorpi et al., 1995; 7795646, Koivisto et al., 1997; 9000575, Haapala et al., 2007; 17217995, Schrecengost and Knudsen, 2013; 23806491, Schmidt and Tindall, 2013; 23565753, Grasso et al., 2012; 22722839, Taylor et al., 2010; 20579941, Azad et al., 2015; 25712683, Waltering et al., 2012; 22245783, Gross et al., 2013; ASCO Abstract 11047, Bubendorf et al., 1999; 10029066, Belic et al., 2018; 29574703, Wyatt et al., 2016; 27148695, Sonpavde et al., 2019; 30620391). Some studies have shown that AR amplification was significantly more common for patients who progressed on enzalutamide than for those who progressed on abiraterone or other agents (Azad et al., 2015; 25712683, Aggarwal et al., 2015; ASCO GU Abstract 5068, Attard et al., 2009; 19339269). AR copy number gain is associated with increased Gleason score, increased baseline prostate_specific antigen (PSA), more advanced clinical stage, and disease progression (Waltering et al., 2012; 22245783, Merson et al., 2014; 24481405, Kohli et al., 2020; 32268276), and is significantly associated with worse OS in castration_resistant prostate cancer (CRPC) (Annala et al., 2021; 33836265, Kubota et al., 2021; 33675416, Kohli et al., 2020; 32268276, Kohli et al., 2018; 29858592, Conteduca et al., 2018; 30773204). For patients with CRPC treated with enzalutamide or abiraterone, AR copy number gain or amplification has been associated with worse outcomes (Annala et al., 2021; 34083234, Del Re et al., 2021; 33500577, Conteduca et al., 2017; 28472366, Tolmeijer et al., 2020; DOI: 10.1200/PO.20.00084, Azad et al., 2015; 25712683, Romanel et al., 2015; 26537258, Salvi et al., 2016; 27191887); however, AR amplification does not always correlate with poor outcomes on these treatments (Belic et al., 2018; 29574703, Annala et al., 2018; 29367197). Antiandrogens such as apalutamide, bicalutamide, cyproterone, darolutamide, enobosarm, enzalutamide, flutamide, and nilutamide directly target AR, whereas hormone therapies such as the CYP17A1 inhibitor abiraterone and luteinizing hormone_releasing hormone agonists or antagonists modulate androgen production (Patel et al., 2013; 23819055, Chowdhury and Kirby, 2013; 23724747, Ahmed et al., 1983; 6135909, Smith et al., 2018; 29420164, Fizazi et al., 2019; 30763142, Fizazi et al., 2014; 24974051, Soifer et al., 2012; 22174412, Sartor, 2011; 21808270, Bolton and Lynch 2018; 29438592, Hird et al., 2020; 32278840, Palmieri et al., 2020; SABCS Abstract PD8_10). Resistance to androgen deprivation therapy (ADT) commonly occurs in prostate cancer through mechanisms such as increased AR expression, AR activation by tyrosine kinase_dependent signaling, alterations in AR co_activators, expression of alternatively spliced isoforms of AR mRNAs (AR_Vs), and extragonadal synthesis of androgenic compounds (van der Steen et al., 2013; 23863692, Lee et al., 2013; 24019458, Gowda et al., 2013; 23989930, Liu et al., 2014; 23851510, Wadosky et al., 2016; 27487144). Approaches in clinical and preclinical development for prostate cancer include therapies that target AR nuclear translocation and degradation pathways (Loddick et al., 2013; 23861347, Rathkopf et al., 2013; 24002508, Smith et al., 2016; 27160947, Rathkopf et al., 2017; 28213364, Soh et al., 2013; 24042123, Bianchini et al., 2013; 24169353, Li et al., 2013; 23939374, Gao et al., 2022; ASCO GU Abstract 17), single_agent or combinational approaches to suppress androgen biosynthesis (McKay et al., 2016; 27683182, Fizazi et al., 2022; ASCU GU Abstract 18), and the use of bromodomain and extraterminal (BET) inhibitors that disrupt the interaction between AR and BRD4 (Asangani et al., 2014; 24759320, Asangani et al., 2016; 26792867, Faivre et al., 2017; 27707886, Piha_Paul et al., 2019; 31420359); the latter approach has potential to target AR_Vs (Chan et al., 2015; 25908785, Asangani et al., 2016; 26792867, Faivre et al., 2017; 27707886). Limited clinical and preclinical data suggest that selective p300/CBP bromodomain inhibitors such as inobrodib (Welti et al., 2021; 33431496) and FT7051 (Armstrong et al., 2021; AACR_NCI_EORTC Abstract P202) are active against AR_activated prostate cancer. Extensive clinical data have demonstrated that AR amplification may confer resistance to androgen deprivation therapy (Visakorpi et al., 1995; 7795646, Koivisto et al., 1997; 9000575, Wakostky and Koochekpour, 2016; 27487144, Waltering et al., 2012; 22245783) or androgen receptor signaling inhibitors (ARSIs) such as abiraterone and enzalutamide (Du et al., 2020; 32203070, Dong et al., 2021; 33990090, Kohli et al., 2020; 32268276, McKay et al., 2021; 33849963), although a few studies have suggested that AR amplification confers resistance to enzalutamide but not to abiraterone (Sakamoto et al., 2019; ASCO GI 314), or its presence does not preclude response to ARSIs (Annala et al., 2018; 29367197, Aggarwal et al., 2015; ASCO GU Abstract 5068). AR signaling may promote radioresistance in prostate cancer by transcriptionally upregulating DNA repair genes (Bartek et al., 2013; 24203954). There is preclinical evidence that development of resistance to anti_AR therapies, such as abiraterone and enzalutamide, may engender cross_resistance to the taxanes docetaxel and cabazitaxel (van Soest et al., 2013; 24200698); however, certain AR_Vs may remain sensitive to taxanes (Scher et al., 2016; 27262168, Antonarakis et al., 2015; 26181238). Clinical data from a small Phase 2 study (De Giorgi et al., 2021; 34333554) and a small retrospective analysis (Vlachostergios et al., 2019; AACR Abstract 4865) suggest that AR amplification may be associated with inferior outcomes for patients with CRPC treated with PSMA_targeted radionuclide_based therapies such as lutetium Lu 177 vipivotide tetraxetan (177Lu_PSMA_617). In the context of chemotherapy, AR amplification was associated with favorable outcomes in time to next treatment or OS for patients with metastatic castration_resistant prostate cancer (mCRPC) treated with taxanes versus novel hormonal therapies such as enzalutamide or abiraterone (Graf et al., 2021; 34716049, Conteduca et al., 2018; 30773204). In a meta_analysis study, AR gain did not affect OS and PFS for patients treated with first_line docetaxel or second_ or third_line cabazitaxel but was associated with reduced response in later lines of docetaxel (Tolmeijer et al., 2020; DOI: 10.1200/PO.20.00084). For patients with poor_prognosis CRPC treated with either cabazitaxel followed by androgen receptor pathway inhibitors (ARPIs) or ARPIs followed by cabazitaxel, AR amplification was significantly associated with shorter time to progression for both ARPIs and cabazitaxel, without significant difference observed between the 2 methods of treatment (Annala et al., 2021; 33836265). Although the radioligand therapy 177Lu_PSMA_617 is recommended for patients with PSMA_positive mCRPC previously treated with novel hormonal therapy and a taxane_based chemotherapy (NCCN Prostate Cancer Guidelines, v.4.2022), the presence of AR amplification has been associated with poor outcomes for patients with PSMA_positive mCRPC treated with 177Lu_PSMA_617 in a Phase 2 trial (De Giorgi et al., 2021; 34333554).", "Include": "true", "ClinicalTrialNote": "AR activation may predict sensitivity to selective p300/CBP bromodomain inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03568656", "Include": "true"}, {"nctId": "NCT04575766", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "BCOR", "Include": "true", "Alterations": {"Alteration": {"Name": "S301fs*11", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "8.21", "isEquivocal": "false", "name": "S301fs*11"}}, "Interpretation": "BCOR encodes a transcriptional corepressor that interacts with BCL6 but not with related POZ domain_containing proteins (Huynh et al., 2000; 10898795). BCOR activity is required for normal development; de novo germline mutations in BCOR have been linked to syndromic microphthalmia_2 and oculofaciocardiodental syndrome (Ng et al., 2004; 15004558). BCOR inactivation has been reported in various malignancies, whereas BCOR fusions and internal tandem duplications (ITDs) are characteristic of specific tumor types (Pierron et al., 2012; 22387997, Kao et al., 2016; 27428733, Specht et al., 2016; 26752546, Panagopoulos et al., 2013; 23580382, Antonescu et al., 2014; 24285434, Astolfi et al., 2015; 26516930, Roy et al., 2015; 26573325, Kao et al., 2016; 26945340, Kao et al., 2016; 27428733, Cramer et al., 2017; 28687574, Appay et al., 2017; 28704208). BCOR alteration (mutation or homozygous deletion) has been reported in 5.4% of rhabdomyosarcoma cases, with BCOR alterations occurring more frequently in PAX fusion_negative tumors (7%) than PAX fusion_positive (1.9%) tumors (Shern et al., 2014; 24436047); BCOR mutation has also been reported in 3.2% (3/92) of medulloblastoma cases (Pugh et al., 2012; 22820256). In the context of hematologic disease, BCOR mutation has also been reported in 4% of aplastic anemia cases (Kulasekararaj et al., 2014; 25139356), 4.2% of myelodysplastic syndrome (MDS) cases (Damm et al., 2013; 24047651), 7.2% of chronic myelomonocytic leukemia cases (Damm et al., 2013; 24047651), and 3.8% of normal karyotype acute myeloid leukemia (AML) cases (Grossman et al., 2011; 22012066). Published data investigating the prognostic implications of BCOR mutations or inactivating alterations in solid tumors are generally limited (PubMed, Jun 2022). There are no targeted therapies available to address BCOR alterations.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). The effects of hypermutation on prognosis and clinical features in prostate cancer have not been extensively investigated (PubMed, Feb 2022). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "DNMT3A", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 2174_1G>C", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.39", "isEquivocal": "false", "name": "splice site 2174_1G>C"}}, "Interpretation": "The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation (Trowbridge and Orkin, 2012; 22200773, Ch\u00e9din, 2011; 21507354). The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor (Yang et al., 2011; 21887466, Vallb\u00f6hmer et al., 2006; 16870044, Daskalos et al., 2011; 21351083, Fabbri et al., 2007; 17890317, Gao et al., 2011; 22011581, Kim et al., 2013; 23031157). Alterations such as seen here may disrupt DNMT3A function or expression (Chen et al., 2005; 15861382, Guo et al., 2015; 25383530, Sandoval et al., 2019; 30705090, Zhang et al., 2018; 29414941). DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022). There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI has been reported in 3.1_14.6% of prostate cancer samples (Hall et al., 2016; ASCO Abstract 1523, Cheng et al., 2016; ASCO Abstract 251)(Pritchard et al., 2014; 25255306, Schwarzenbach et al., 2008; 18336598, Suzuki et al., 1995; 7493915). A study of prostate cancer in hereditary nonpolyposis colorectal cancer (HNPCC) families reported MSI_H in 4_50% of cases (Dominguez_Valentin et al., 2016; 27013479, Rosty et al., 2014; 25117503, Ahman et al., 2001; 11251526). For patients with advanced prostate cancer, dMMR/MSI status was associated with shorter median OS compared with patients with proficient MMR (3.8 vs. 7.0 years) by univariate and multivariate analysis (adjusted HR=4.09; P=0.005)(Rodrigues et al., 2018; 30382943). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "T125R", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "66.96", "isEquivocal": "false", "name": "T125R"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 18_40% of prostate cancers (Kumar et al., 2011; 21949389, Beltran et al., 2013; 22981675). Overexpression of p53, which is indicative of TP53 dysregulation, has been reported to be significantly more common in late_stage and hormone_refractory prostate cancers and has been found to be associated with prostate_specific antigen (PSA) recurrence in low_ and intermediate_grade prostate cancer (Schlomm et al., 2008; 18552821). TP53 loss has been found to be associated with prostate cancer_specific mortality in univariate analysis (Liu et al., 2013; 23609948). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "AR", "Alteration": "amplification", "Title": "Study to Evaluate CCS1477 in Advanced Tumours", "StudyPhase": "PHASE 1/2", "Target": "EP300, CREBBP", "Locations": "Stockholm (Sweden), Amsterdam (Netherlands), Newcastle (United Kingdom), Edinburgh (United Kingdom), Glasgow (United Kingdom), Cambridge (United Kingdom), Manchester (United Kingdom), Leicester (United Kingdom), Sutton (United Kingdom), Birmingham (United Kingdom)", "NCTID": "NCT03568656", "Note": "AR activation may predict sensitivity to selective p300/CBP bromodomain inhibitors.", "Include": "true"}, {"Gene": "AR", "Alteration": "amplification", "Title": "A Study of FT_7051 in Men With MCRPC", "StudyPhase": "PHASE 1", "Target": "CREBBP, EP300", "Locations": "Colorado, Arizona, Illinois, Missouri, New York, Maryland, North Carolina, South Carolina", "NCTID": "NCT04575766", "Note": "AR activation may predict sensitivity to selective p300/CBP bromodomain inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "22124843", "FullCitation": "Niraula S, et al. Horm Cancer (2012) pmid: 22124843", "Include": "true"}, {"number": "1", "ReferenceId": "24481405", "FullCitation": "Merson S, et al. Br J Cancer (2014) pmid: 24481405", "Include": "true"}, {"number": "2", "ReferenceId": "7795646", "FullCitation": "Visakorpi T, et al. Nat. Genet. (1995) pmid: 7795646", "Include": "true"}, {"number": "3", "ReferenceId": "9000575", "FullCitation": "Koivisto P, et al. Cancer Res. (1997) pmid: 9000575", "Include": "true"}, {"number": "4", "ReferenceId": "10029066", "FullCitation": "Bubendorf L, et al. Cancer Res. (1999) pmid: 10029066", "Include": "true"}, {"number": "5", "ReferenceId": "11325816", "FullCitation": "Linja MJ, et al. Cancer Res (2001) pmid: 11325816", "Include": "true"}, {"number": "6", "ReferenceId": "11061898", "FullCitation": "Palmberg C, et al. J. Urol. (2000) pmid: 11061898", "Include": "true"}, {"number": "7", "ReferenceId": "17217995", "FullCitation": "Haapala K, et al. Hum. Pathol. (2007) pmid: 17217995", "Include": "true"}, {"number": "8", "ReferenceId": "23806491", "FullCitation": "Schrecengost R, et al. Semin. Oncol. (2013) pmid: 23806491", "Include": "true"}, {"number": "9", "ReferenceId": "23565753", "FullCitation": "Schmidt LJ, et al. Curr Drug Targets (2013) pmid: 23565753", "Include": "true"}, {"number": "10", "ReferenceId": "22722839", "FullCitation": "Grasso CS, et al. Nature (2012) pmid: 22722839", "Include": "true"}, {"number": "11", "ReferenceId": "20579941", "FullCitation": "Taylor BS, et al. Cancer Cell (2010) pmid: 20579941", "Include": "true"}, {"number": "12", "ReferenceId": "25712683", "FullCitation": "Azad AA, et al. Clin. Cancer Res. (2015) pmid: 25712683", "Include": "true"}, {"number": "13", "ReferenceId": "22245783", "FullCitation": "Waltering KK, et al. Mol Cell Endocrinol (2012) pmid: 22245783", "Include": "true"}, {"number": "14", "ReferenceId": "29574703", "FullCitation": "Belic J, et al. Int J Cancer (2018) pmid: 29574703", "Include": "true"}, {"number": "15", "ReferenceId": "27148695", "FullCitation": "Wyatt AW, et al. JAMA Oncol (2016) pmid: 27148695", "Include": "true"}, {"number": "16", "ReferenceId": "30620391", "FullCitation": "Sonpavde G, et al. Cancer (2019) pmid: 30620391", "Include": "true"}, {"number": "17", "ReferenceId": "19339269", "FullCitation": "Attard G, et al. Cancer Res (2009) pmid: 19339269", "Include": "true"}, {"number": "18", "ReferenceId": "32268276", "FullCitation": "Kohli M, et al. EBioMedicine (2020) pmid: 32268276", "Include": "true"}, {"number": "19", "ReferenceId": "33836265", "FullCitation": "Annala M, et al. Ann Oncol (2021) pmid: 33836265", "Include": "true"}, {"number": "20", "ReferenceId": "33675416", "FullCitation": "Kubota Y, et al. World J Urol (2021) pmid: 33675416", "Include": "true"}, {"number": "21", "ReferenceId": "29858592", "FullCitation": "Kohli M, et al. Prostate Cancer Prostatic Dis (2018) pmid: 29858592", "Include": "true"}, {"number": "22", "ReferenceId": "30773204", "FullCitation": "Conteduca V, et al. Eur Urol (2019) pmid: 30773204", "Include": "true"}, {"number": "23", "ReferenceId": "34083234", "FullCitation": "Annala M, et al. Clin Cancer Res (2021) pmid: 34083234", "Include": "true"}, {"number": "24", "ReferenceId": "33500577", "FullCitation": "Del Re M, et al. Prostate Cancer Prostatic Dis (2021) pmid: 33500577", "Include": "true"}, {"number": "25", "ReferenceId": "28472366", "FullCitation": "Conteduca V, et al. Ann Oncol (2017) pmid: 28472366", "Include": "true"}, {"number": "26", "ReferenceId": "26537258", "FullCitation": "Romanel A, et al. Sci Transl Med (2015) pmid: 26537258", "Include": "true"}, {"number": "27", "ReferenceId": "27191887", "FullCitation": "Salvi S, et al. Oncotarget (2016) pmid: 27191887", "Include": "true"}, {"number": "28", "ReferenceId": "29367197", "FullCitation": "Annala M, et al. Cancer Discov (2018) pmid: 29367197", "Include": "true"}, {"number": "29", "ReferenceId": "23819055", "FullCitation": "Patel JC, et al. Prostate Cancer (2013) pmid: 23819055", "Include": "true"}, {"number": "30", "ReferenceId": "23724747", "FullCitation": "Chowdhury S, et al. Practitioner (2013) pmid: 23724747", "Include": "true"}, {"number": "31", "ReferenceId": "6135909", "FullCitation": "Ahmed SR, et al. Lancet (1983) pmid: 6135909", "Include": "true"}, {"number": "32", "ReferenceId": "29420164", "FullCitation": "Smith MR, et al. N. Engl. J. Med. (2018) pmid: 29420164", "Include": "true"}, {"number": "33", "ReferenceId": "30763142", "FullCitation": "Fizazi K, et al. N. Engl. J. Med. (2019) pmid: 30763142", "Include": "true"}, {"number": "34", "ReferenceId": "24974051", "FullCitation": "Fizazi K, et al. Lancet Oncol. (2014) pmid: 24974051", "Include": "true"}, {"number": "35", "ReferenceId": "22174412", "FullCitation": "Soifer HS, et al. J. Biol. Chem. (2012) pmid: 22174412", "Include": "true"}, {"number": "36", "ReferenceId": "21808270", "FullCitation": "Nat Rev Clin Oncol (2011) pmid: 21808270", "Include": "true"}, {"number": "37", "ReferenceId": "32278840", "FullCitation": "Hird AE, et al. Clin Genitourin Cancer (2020) pmid: 32278840", "Include": "true"}, {"number": "38", "ReferenceId": "23863692", "FullCitation": "van der Steen T, et al. Int J Mol Sci (2013) pmid: 23863692", "Include": "true"}, {"number": "39", "ReferenceId": "24019458", "FullCitation": "Lee E, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 24019458", "Include": "true"}, {"number": "40", "ReferenceId": "23989930", "FullCitation": "Gowda PS, et al. Mol. Cancer Res. (2013) pmid: 23989930", "Include": "true"}, {"number": "41", "ReferenceId": "23851510", "FullCitation": "Liu LL, et al. Oncogene (2014) pmid: 23851510", "Include": "true"}, {"number": "42", "ReferenceId": "27487144", "FullCitation": "Wadosky KM, et al. Oncotarget (2016) pmid: 27487144", "Include": "true"}, {"number": "43", "ReferenceId": "23861347", "FullCitation": "Loddick SA, et al. Mol. Cancer Ther. (2013) pmid: 23861347", "Include": "true"}, {"number": "44", "ReferenceId": "24002508", "FullCitation": "Rathkopf DE, et al. J. Clin. Oncol. (2013) pmid: 24002508", "Include": "true"}, {"number": "45", "ReferenceId": "27160947", "FullCitation": "Smith MR, et al. Eur. Urol. (2016) pmid: 27160947", "Include": "true"}, {"number": "46", "ReferenceId": "28213364", "FullCitation": "Rathkopf DE, et al. Clin. Cancer Res. (2017) pmid: 28213364", "Include": "true"}, {"number": "47", "ReferenceId": "24042123", "FullCitation": "Soh SF, et al. J Pharm Biomed Anal (2014) pmid: 24042123", "Include": "true"}, {"number": "48", "ReferenceId": "24169353", "FullCitation": "Bianchini D, et al. Br. J. Cancer (2013) pmid: 24169353", "Include": "true"}, {"number": "49", "ReferenceId": "23939374", "FullCitation": "Li H, et al. Mol. Cancer Ther. (2013) pmid: 23939374", "Include": "true"}, {"number": "50", "ReferenceId": "27683182", "FullCitation": "McKay RR, et al. Clin. Cancer Res. (2017) pmid: 27683182", "Include": "true"}, {"number": "51", "ReferenceId": "24759320", "FullCitation": "Asangani IA, et al. Nature (2014) pmid: 24759320", "Include": "true"}, {"number": "52", "ReferenceId": "26792867", "FullCitation": "Asangani IA, et al. Mol. Cancer Res. (2016) pmid: 26792867", "Include": "true"}, {"number": "53", "ReferenceId": "27707886", "FullCitation": "Faivre EJ, et al. Mol. Cancer Res. (2017) pmid: 27707886", "Include": "true"}, {"number": "54", "ReferenceId": "31420359", "FullCitation": "Piha_Paul SA, et al. Clin. Cancer Res. (2019) pmid: 31420359", "Include": "true"}, {"number": "55", "ReferenceId": "25908785", "FullCitation": "Chan SC, et al. Nucleic Acids Res. (2015) pmid: 25908785", "Include": "true"}, {"number": "56", "ReferenceId": "33431496", "FullCitation": "Welti J, et al. Cancer Discov (2021) pmid: 33431496", "Include": "true"}, {"number": "57", "ReferenceId": "32203070", "FullCitation": "Du M, et al. Prostate Cancer Prostatic Dis (2020) pmid: 32203070", "Include": "true"}, {"number": "58", "ReferenceId": "33990090", "FullCitation": "Dong B, et al. J Natl Compr Canc Netw (2021) pmid: 33990090", "Include": "true"}, {"number": "59", "ReferenceId": "33849963", "FullCitation": "McKay RR, et al. Clin Cancer Res (2021) pmid: 33849963", "Include": "true"}, {"number": "60", "ReferenceId": "24203954", "FullCitation": "Bartek J, et al. Cancer Discov (2013) pmid: 24203954", "Include": "true"}, {"number": "61", "ReferenceId": "24200698", "FullCitation": "van Soest RJ, et al. Eur. J. Cancer (2013) pmid: 24200698", "Include": "true"}, {"number": "62", "ReferenceId": "27262168", "FullCitation": "Scher HI, et al. JAMA Oncol (2016) pmid: 27262168", "Include": "true"}, {"number": "63", "ReferenceId": "26181238", "FullCitation": "Antonarakis ES, et al. JAMA Oncol (2015) pmid: 26181238", "Include": "true"}, {"number": "64", "ReferenceId": "34333554", "FullCitation": "De Giorgi U, et al. Br J Cancer (2021) pmid: 34333554", "Include": "true"}, {"number": "65", "ReferenceId": "34716049", "FullCitation": "Graf RP, et al. Eur Urol (2021) pmid: 34716049", "Include": "true"}, {"number": "66", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "67", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "68", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "69", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "70", "ReferenceId": "18336598", "FullCitation": "Schwarzenbach H, et al. BJU Int. (2008) pmid: 18336598", "Include": "true"}, {"number": "71", "ReferenceId": "7493915", "FullCitation": "Suzuki H, et al. Jpn. J. Cancer Res. (1995) pmid: 7493915", "Include": "true"}, {"number": "72", "ReferenceId": "27013479", "FullCitation": "Dominguez_Valentin M, et al. BMC Urol (2016) pmid: 27013479", "Include": "true"}, {"number": "73", "ReferenceId": "25117503", "FullCitation": "Rosty C, et al. Fam. Cancer (2014) pmid: 25117503", "Include": "true"}, {"number": "74", "ReferenceId": "11251526", "FullCitation": "Ahman AK, et al. BJU Int. (2001) pmid: 11251526", "Include": "true"}, {"number": "75", "ReferenceId": "30382943", "FullCitation": "Rodrigues DN, et al. J. Clin. Invest. (2018) pmid: 30382943", "Include": "true"}, {"number": "76", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "77", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "78", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "79", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "80", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "81", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "82", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "83", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "84", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "85", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "86", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "87", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "88", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "89", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "90", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "91", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "92", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "93", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "94", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "95", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "96", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "97", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "98", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "99", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "100", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "101", "ReferenceId": "22200773", "FullCitation": "Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773", "Include": "true"}, {"number": "102", "ReferenceId": "21507354", "FullCitation": "Prog Mol Biol Transl Sci (2011) pmid: 21507354", "Include": "true"}, {"number": "103", "ReferenceId": "21887466", "FullCitation": "Yang J, et al. Mol Med Rep () pmid: 21887466", "Include": "true"}, {"number": "104", "ReferenceId": "16870044", "FullCitation": "Vallb\u00f6hmer D, et al. Clin Lung Cancer (2006) pmid: 16870044", "Include": "true"}, {"number": "105", "ReferenceId": "21351083", "FullCitation": "Daskalos A, et al. Cancer (2011) pmid: 21351083", "Include": "true"}, {"number": "106", "ReferenceId": "17890317", "FullCitation": "Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317", "Include": "true"}, {"number": "107", "ReferenceId": "22011581", "FullCitation": "Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581", "Include": "true"}, {"number": "108", "ReferenceId": "23031157", "FullCitation": "Kim MS, et al. APMIS (2013) pmid: 23031157", "Include": "true"}, {"number": "109", "ReferenceId": "15861382", "FullCitation": "Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382", "Include": "true"}, {"number": "110", "ReferenceId": "25383530", "FullCitation": "Guo X, et al. Nature (2015) pmid: 25383530", "Include": "true"}, {"number": "111", "ReferenceId": "30705090", "FullCitation": "Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090", "Include": "true"}, {"number": "112", "ReferenceId": "29414941", "FullCitation": "Zhang ZM, et al. Nature (2018) pmid: 29414941", "Include": "true"}, {"number": "113", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "114", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "115", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "116", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "117", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "118", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "119", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "120", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "121", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "122", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "123", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "124", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "125", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "126", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "127", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "128", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "129", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "130", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "131", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "132", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "133", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "134", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "135", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "136", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "137", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "138", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "139", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "140", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "141", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}, {"number": "142", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "143", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "144", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "145", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "146", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "147", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "148", "ReferenceId": "21949389", "FullCitation": "Kumar A, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 21949389", "Include": "true"}, {"number": "149", "ReferenceId": "22981675", "FullCitation": "Beltran H, et al. Eur. Urol. (2013) pmid: 22981675", "Include": "true"}, {"number": "150", "ReferenceId": "18552821", "FullCitation": "Schlomm T, et al. Mod. Pathol. (2008) pmid: 18552821", "Include": "true"}, {"number": "151", "ReferenceId": "23609948", "FullCitation": "Liu W, et al. Cancer (2013) pmid: 23609948", "Include": "true"}, {"number": "152", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "153", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "154", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "155", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "156", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "157", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "158", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "159", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "160", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "161", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "162", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "163", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "164", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "165", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "166", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "167", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "168", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "169", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "170", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "171", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "172", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "173", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "174", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "175", "ReferenceId": "10898795", "FullCitation": "Huynh KD, et al. Genes Dev. (2000) pmid: 10898795", "Include": "true"}, {"number": "176", "ReferenceId": "15004558", "FullCitation": "Ng D, et al. Nat. Genet. (2004) pmid: 15004558", "Include": "true"}, {"number": "177", "ReferenceId": "22387997", "FullCitation": "Pierron G, et al. Nat. Genet. (2012) pmid: 22387997", "Include": "true"}, {"number": "178", "ReferenceId": "27428733", "FullCitation": "Kao YC, et al. Am. J. Surg. Pathol. (2016) pmid: 27428733", "Include": "true"}, {"number": "179", "ReferenceId": "26752546", "FullCitation": "Specht K, et al. Am. J. Surg. Pathol. (2016) pmid: 26752546", "Include": "true"}, {"number": "180", "ReferenceId": "23580382", "FullCitation": "Panagopoulos I, et al. Genes Chromosomes Cancer (2013) pmid: 23580382", "Include": "true"}, {"number": "181", "ReferenceId": "24285434", "FullCitation": "Antonescu CR, et al. Genes Chromosomes Cancer (2014) pmid: 24285434", "Include": "true"}, {"number": "182", "ReferenceId": "26516930", "FullCitation": "Astolfi A, et al. Oncotarget (2015) pmid: 26516930", "Include": "true"}, {"number": "183", "ReferenceId": "26573325", "FullCitation": "Roy A, et al. Nat Commun (2015) pmid: 26573325", "Include": "true"}, {"number": "184", "ReferenceId": "26945340", "FullCitation": "Kao YC, et al. Am. J. Surg. Pathol. (2016) pmid: 26945340", "Include": "true"}, {"number": "185", "ReferenceId": "28687574", "FullCitation": "Cramer SL, et al. J Natl Compr Canc Netw (2017) pmid: 28687574", "Include": "true"}, {"number": "186", "ReferenceId": "28704208", "FullCitation": "Appay R, et al. Am. J. Surg. Pathol. (2017) pmid: 28704208", "Include": "true"}, {"number": "187", "ReferenceId": "24436047", "FullCitation": "Shern JF, et al. Cancer Discov (2014) pmid: 24436047", "Include": "true"}, {"number": "188", "ReferenceId": "22820256", "FullCitation": "Pugh TJ, et al. Nature (2012) pmid: 22820256", "Include": "true"}, {"number": "189", "ReferenceId": "25139356", "FullCitation": "Kulasekararaj AG, et al. Blood (2014) pmid: 25139356", "Include": "true"}, {"number": "190", "ReferenceId": "24047651", "FullCitation": "Damm F, et al. Blood (2013) pmid: 24047651", "Include": "true"}, {"number": "191", "ReferenceId": "22012066", "FullCitation": "Grossmann V, et al. Blood (2011) pmid: 22012066", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_12_21 18:20:28", "OpName": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "64%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PROSTATE", "disease_ontology": "Prostate acinar adenocarcinoma", "flowcell_analysis": "2000026330", "gender": "male", "pathology_diagnosis": "Prostate Adenocarcinoma", "pipeline_version": "v3.17.0", "purity_assessment": "66.2", "specimen": "ORD_1523346_01*US1458779.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1523346_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1458779.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.6696", "cds_effect": "374C>G", "depth": "3108", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "66.96", "position": "chr17:7579313", "protein_effect": "T125R", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"allele_fraction": "0.0039", "cds_effect": "2174_1G>C", "depth": "1541", "equivocal": "false", "functional_effect": "splice", "gene": "DNMT3A", "percent_reads": "0.39", "position": "chr2:25463320", "protein_effect": "splice site 2174_1G>C", "status": "likely", "strand": "_", "transcript": "NM_022552", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"allele_fraction": "0.6396", "cds_effect": "2168T>G", "depth": "555", "equivocal": "false", "functional_effect": "missense", "gene": "CUL3", "percent_reads": "63.96", "position": "chr2:225342924", "protein_effect": "V723G", "status": "unknown", "strand": "_", "transcript": "NM_003590", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"allele_fraction": "0.4924", "cds_effect": "661G>A", "depth": "6475", "equivocal": "false", "functional_effect": "missense", "gene": "PALB2", "percent_reads": "49.24", "position": "chr16:23647206", "protein_effect": "V221I", "status": "unknown", "strand": "_", "transcript": "NM_024675", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"allele_fraction": "0.248", "cds_effect": "425T>C", "depth": "2928", "equivocal": "false", "functional_effect": "missense", "gene": "CD274", "percent_reads": "24.8", "position": "chr9:5462864", "protein_effect": "L142S", "status": "unknown", "strand": "+", "transcript": "NM_014143", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"allele_fraction": "0.0075", "cds_effect": "809G>A", "depth": "1997", "equivocal": "false", "functional_effect": "missense", "gene": "DAXX", "percent_reads": "0.75", "position": "chr6:33288743", "protein_effect": "R270H", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"allele_fraction": "0.4784", "cds_effect": "488A>G", "depth": "1294", "equivocal": "false", "functional_effect": "missense", "gene": "CBFB", "percent_reads": "47.84", "position": "chr16:67116204", "protein_effect": "E163G", "status": "unknown", "strand": "+", "transcript": "NM_022845", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"allele_fraction": "0.0821", "cds_effect": "901_902insT", "depth": "816", "equivocal": "false", "functional_effect": "frameshift", "gene": "BCOR", "percent_reads": "8.21", "position": "chrX:39933697", "protein_effect": "S301fs*11", "status": "likely", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"allele_fraction": "0.5177", "cds_effect": "2138C>T", "depth": "1188", "equivocal": "false", "functional_effect": "missense", "gene": "KIT", "percent_reads": "51.77", "position": "chr4:55595648", "protein_effect": "S713F", "status": "unknown", "strand": "+", "transcript": "NM_000222", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "7", "equivocal": "true", "gene": "SYK", "number_of_exons": "13 of 13", "position": "chr9:93606180_93657910", "ratio": "2.2", "status": "unknown", "type": "amplification"}, {"copy_number": "28", "equivocal": "false", "gene": "AR", "number_of_exons": "9 of 9", "position": "chrX:66430630_66980746", "ratio": "6.73", "status": "known", "type": "amplification"}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "64", "status": "unknown", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"organism": "HHV_4", "reads_per_million": "51", "status": "unknown", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}, {"organism": "HHV_8", "reads_per_million": "33", "status": "unknown", "dna_evidence": {"sample": "SQ_US1458779.01_1"}}]}}}}}